Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agree on that
So back to the interesting but who knows category looking back at a similar filing Frigate did with Oxigene back on Feb 12, 2014 and how the stock traded right after..hmmmm
The filing: http://www.sec.gov/Archives/edgar/data/908259/000119312514060363/d680287dsc13g.htm
The chart:
http://finance.yahoo.com/echarts?s=OXGN+Interactive#{"range":"2y","allowChartStacking":true}
Will it fly up or down? There is a lot of "short" term thinking and it will be interesting to see in a week what the pps is.
Anyone know if the shelf filing is closed out. Last I check they had more shares to go. Any updates?
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=9999999995-15-001971%2Etxt&FilePath=%5C2015%5C07%5C20%5C&CoName=CERES%2C+INC%2E&FormType=EFFECT&RcvdDate=7%2F17%2F2015&pdf=
Amen on that one.
Makes you wonder who is selling and buying.....
CERE made the holy grail....CNBC Ticker, LOL
looks like the band is ready to play today. Wonder if the run will stick or is it another flash in the pan.
Holly smokes, everyone wants to get on the train today.......
In the better late than never category I guess:
Ceres Awarded Patent for iCODE™ Trait Development System
Operates like one too!!!
do a search for Ceres at http://patft.uspto.gov/netahtml/PTO/search-bool.html
Every Tuesday the new patents are posted.
United States Patent 9,101,100
Pennell , et al. August 11, 2015
Methods and materials for high throughput testing of transgene combinations
Abstract
High throughput methods are described for identifying combinations of transgenes that can be used to improve a phenotypic feature in an organism. Large populations of organisms (e.g., plants) containing different combinations of transgenes as well as different promoter-coding sequence combinations can be assessed using the methods.
Inventors: Pennell; Roger I. (Malibu, CA), Hamilton; Richard (Calabasas, CA), Portereiko; Michael F. (Thousand Oaks, CA)
Applicant:
Name City State Country Type
Ceres, Inc.
Thousand Oaks
CA
US
Assignee: Ceres, Inc. (Thousand Oaks, CA)
Family ID: 1000000626467
Appl. No.: 14/327,217
Filed: July 9, 2014
New-Patent - I wonder if they will announce it now that the new kids are on the block and the seasoned ones have probably covered? Is this ICODE or part of it?
United States Patent 9,101,100
Pennell , et al. August 11, 2015
Methods and materials for high throughput testing of transgene combinations
1. A method for identifying a combination of genetic elements responsible for a desirable phenotype of a plant, wherein said method comprises: (a) selecting at least four target transgenes, wherein each target transgene of said at least four target transgenes comprises a regulatory region comprising an upstream activating sequence operably linked to a nucleotide sequence to be expressed, whereby said upstream activating sequence of each of said at least four target transgenes is the same or different; (b) selecting at least two activator transgenes, wherein each activator transgene comprises a plant promoter operably linked to a sequence encoding a chimeric polypeptide comprising a DNA binding domain fused to a transcription activation domain, wherein each DNA binding domain of said at least two chimeric polypeptides binds to the upstream activating sequence comprised within said regulatory region of at least one of said at least four target transgenes; (c) obtaining a first parental plant and a second parental plant, wherein each of said at least four target transgenes and said at least two activator transgenes (i) is individually present in either said first parental plant or said second parental plant, (ii) is unlinked from each of the other of said at least four target transgenes and said at least two activator transgenes that are present within the same said first parental plant or said second parental plant, and (iii) is in a hemizygous state within said first parental plant or said second parental plant; (d) sexually crossing said first parental plant and said second parental plant to produce a population of progeny plants, whereby said population of progeny plants has different combinations of said at least four target transgenes and said at least two activator transgenes; (e) comparing different plants of said population of progeny plants to one another and selecting at least one progeny plant from said population as having said desirable phenotype to obtain a selected progeny plant; and (f) determining which target transgenes and activator transgenes are present within said selected progeny plant, thereby identifying a combination of genetic elements responsible for said desirable phenotype of a plant.
Hopefully someone kicks managements a$$ for the shareholders that are left sake. Frigate and M5V look to be a bit more aggressive with management from the news when searched.
Strange way to do things if you ask me. The "sales commission" is a nice 125K, sweet deal for the broker LADENBURG THALMANN & CO. INC.
Now here is another interesting twist. Management buying to fund the company???
Small Company Offering and Sale of Securities Without Registration (d)
http://ih.advfn.com/p.php?pid=nmona&article=68072087&symbol=CERE
At what point does a class action get started for $CERE? The golden rule is sure ignored by management IMO.
Saw the filing today. Kudos to the CEO for creating shareholder value....not
Hamilton and the rest of management are showing their colors and running it as the true penny stock that it is. Any "investors" money has been handed over to the hedge funds running the show now if you asked me and my opinion counted. They only placed a small fraction of shares from the filing so it ain't over. The strange thing that they don't even try to move the stock up to even attempt a P&D. They just dump since they probably made enough when it ran up on 16M shares and they shorted it all the way and can now cover thanks to the company.
No wonder people don't want to put money in the stock market.
PS. IMO they will take it private at some point when the value is down to nothing and then reap the benefits one more time. (that is my opinion and I am sticking to it)
I hope I am wrong.
The meat from the filing if you ask me. See the bold text..... the cover as stock said....
(jj) Acknowledgment Regarding Purchaser’s Trading Activity. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except for Sections 3.2(g) and 4.15 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or “derivative” securities based on securities issued by the Company or to hold the Securities for any specified term (other than as required by the federal securities laws), (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales or “derivative” transactions, before or after the closing of this or future private placement transactions, may negatively impact the market price of the Company’s publicly-traded securities, (iii) any Purchaser, and counter-parties in “derivative” transactions to which any such Purchaser is a party, directly or indirectly, may presently have a “short” position in the Common Stock and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm’s length counter-party in any “derivative” transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during the period that the Securities are outstanding, including, without limitation, during the periods that the value of the Warrant Shares deliverable with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce the value of the existing stockholders’ equity interests in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.
and I really wonder about this statement. Sounds good but really?
(kk) Regulation M Compliance . The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with the placement of the Securities.
Seems like others have to let people know about the companies patents and new ones getting issued.
Ceres : Patent Issued for Sequence-Determined DNA Fragments with Regulatory Functions
http://www.4-traders.com/CERES-INC-21683463/news/Ceres--Patent-Issued-for-Sequence-Determined-DNA-Fragments-with-Regulatory-Functions-20772074/
Thanks, the penny land mentality that Hamilton and his cronies have soured my view. I actually got involved years ago since I thought it was a good company with good technology that the world could use. They obviously don't operate it that way and whomever is pulling the financial strings is killing it. Who knows and with my luck some block buster release comes out tomorrow now that they have drained any retail and it goes the other way. If it does oh well. They seem to hold out the press releases and they are 2 patents behind on News, but who is counting.
Good luck and wish the best.
Done and out, learned a lesson the hard way and wishful thinking would lead me to believe Hamilton will pay the price for the apparent collusion that the company has with the hedgefunds and his disregard for shareholders. Ripe for a CA, but doubt that will happen. All my tainted opinion and no one else's.
GLTA
Laughable....
The number of shares of Common Stock that will be outstanding after this offering is based on 6,032,222 shares outstanding as of May 31, 2015, and excludes:
• 423,082 shares of Common Stock issuable upon exercise of options to purchase our Common Stock outstanding as of May 31, 2015 at a weighted average exercise price of $42.82 per share;
• 320,255 shares of Common Stock issuable upon exercise of warrants to purchase our Common Stock outstanding as of May 31, 2015 at a weighted average exercise price of $134.48 per share;
Don't think we will see these ever in the money and exercised.
No doubt and hopefully they get theirs someday. Karma comes around and hits when you least expect it.
With warrants to buy in 6 months at a buck sixty or so makes me think we have not seen the last spike. Perfect opportunity to guarantee a cover and even with the new shares this is still a low floater. I would have expected more shares to be traded (dumped) today on the news as well. Thoughts?
Run like a true penny stock. Should have know better.
Hosed by the pros
Things that make you go hmmm,
http://www.accountingtools.com/take-company-private
LMAO, I wish. Then again, taking it private might make sense since the share price is in the dumps for many reasons. Too bad no one pays much attention to CERE.
The patent further builds on this prior patent and surprisingly enough they released news on it here last year.
http://www.ceres.net/news/NewsReleases/2014/05-12-14-News-Rel.html
I do not understand the selective way they release news on the IP they have. It is almost as they want the price down so they can take it private. Just my opinion which is worth about a tin can of sardines.
Another New Patent for $CERE.....
United States Patent 9,085,771
Alexandrov , et al. July 21, 2015
Sequence-determined DNA fragments with regulatory functions
Abstract
The present invention provides DNA molecules that constitute fragments of the genome of a plant, and polypeptides encoded thereby. The DNA molecules are useful for specifying a gene product in cells, either as a promoter or as a protein coding sequence or as an UTR or as a 3' termination sequence, and are also useful in controlling the behavior of a gene in the chromosome, in controlling the expression of a gene or as tools for genetic mapping, recognizing or isolating identical or related DNA fragments, or identification of a particular individual organism, or for clustering of a group of organisms with a common trait.
The notice of effectiveness filed today certainly does not describe managements ability to market the company. Just sayin....
Short Interest Update -
Ceres, Inc. (NASDAQ:CERE), A drop of 36,121 shares or 7.9% was seen in the short interest of Ceres, Inc.. Even as the interest dropped from 455,656 shares on June 15,2015 to 419,535 shares on June 30,2015, the days to cover came in at 3. The updated interest stood at 7.6% of the stocks floats. The shares has an average daily volume of 144,140 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on July 10th.
Shares of Ceres, Inc. appreciated by 3.85% during the last five trading days but lost 14.86% on a 4-week basis. Ceres, Inc. has dropped 7.35% during the last 3-month period . Year-to-Date the stock performance stands at -1.56%.
Ceres, Inc. (NASDAQ:CERE) rose 4.42% or 0.08 points on Monday and made its way into the gainers of the day. After trading began at $1.84 the stock was seen hitting $1.94 as a peak level and $1.8201 as the lowest level. The stock ended up at $1.89. The daily volume was measured at 53,755 shares. The 52-week high of the share price is $6 and the 52-week low is $1.448. The company has a market cap of $11 million.
Ceres, Inc. (Ceres) is an agricultural biotechnology company selling seeds to produce renewable biomass feedstocks. The Companys large-scale commercial products are sweet sorghum varieties that can be used as a drop-in feedstock to extend the operating season of Brazilian sugarcane-to-ethanol mills. Its products include sweet sorghum, high biomass sorghum, switchgrass, miscanthus and row crops. Its energy crops can also be used for the production of second-generation biofuels and bio-based chemicals, including cellulosic ethanol, butanol, jet fuel, diesel-like molecules and gasoline-like molecules, from non-food biomass. Baseload utility scale electric power can also be generated from the biomass feedstocks grown from its seeds. Ceres has sold switchgrass and high biomass sorghum seeds in the United States under its Blade Energy Crops (Blade) brand. In January 2010, the Company incorporated a subsidiary, Ceres Sementes do Brasil Ltda.
http://thedailyrover.com/short-interest-update-of-ceres-inc-nasdaqcere/
No doubt, looking like it is set up nicely for a run. It would be real nice if a bit of good news was in the pipeline for tomorrow.
Works for me and it would be nice for CERE to close over 2. One can dream.
Shorts for CERE dropped a tad bit as of 6/30
Settlement Date 6/30/2015
Short Interest 419,535
Avg Daily Share Volume 144,140
Days To Cover 2.910608
http://www.nasdaq.com/symbol/cere/short-interest
Need more of this :
· Ceres has entered into a multi-year collaboration with a leading agricultural producer to develop improved crop varieties with higher yields, accelerated growth and greater resilience to drought conditions. The development and commercialization program will be fully funded by the company’s collaboration partner. Payments to the company are expected to exceed $1 million by mid-2016. Ceres is also entitled to royalties for new cultivars commercialized under the agreement.
Thanks, will listen later and am curious if there will be at one analyst asking questions. So far the last two have been void and that would be a +. Monday will be interesting and it would be nice if they would actually release some good news and not leak it.
I think so and if they can get some financing that does not kill them they can turn the corner IMO. Losing less and increasing rev.
The company reported that it has signed a collaboration and license agreement with a leading agricultural producer to introduce Ceres' biotech traits following positive results from greenhouse and field evaluations. Separately, the company announced that it has substantially increased plantings of its commercial forage sorghum hybrids in the U.S. over the prior year.
Ceres President and CEO Richard Hamilton noted that the company continues to realign its focus toward food and forage opportunities and biotechnology traits for sugarcane and other crops. "Our core technology platforms and biotech traits provide multiple opportunities for out-licensing by crop, geography and market. Our strategy is to continue to build our proprietary sorghum seed business while we advance our biotech traits and technology toward commercialization. As we demonstrated this quarter, the more advanced these traits and products are in our pipeline, the more valuable they can become."
Paul Kuc, Ceres Chief Financial Officer, reported that the company is actively reviewing a number of potential financing options and further cost reduction measures to extend its working capital. "We continue to closely monitor expenses and intend to make further cost reductions in order to direct greater resources toward improved forages for dairy and meat production and biotech traits for sugarcane and other crops."
Business Highlights and Outlook
For the 2015 growing season in North America, total plantings of Ceres forage sorghum hybrids are expected to cover more than 3,000 acres, compared to approximately 600 acres planted the previous season. The increase in planted acres is primarily due to an increase in the number of customers evaluating the company's products for potentially larger-scale use. Drought and water supply concerns in certain regions of the U.S. positively influenced customer planting decisions of Ceres' forage sorghum hybrids. The company also expanded field evaluations of its biotech traits in sorghum in the United States following successful field trials last season. Performance results for both its traditionally developed hybrids and biotech traits are expected by the end of the calendar year. Ceres added three additional seed distributors for its products in the U.S. and its territories.
Ceres has entered into a multi-year collaboration with a leading agricultural producer to develop improved crop varieties with higher yields, accelerated growth and greater resilience to drought conditions. The development and commercialization program will be fully funded by the company's collaboration partner. Payments to the company are expected to exceed $1 million by mid-2016. Ceres is also entitled to royalties for new cultivars commercialized under the agreement.
In May 2015, the company reported that its bioinformatics software, Persephone, was licensed to global seed potato developer, HZPC Holland BV. Persephone software is also being evaluated by new potential customers in plant genomics as well as in biomedical research and diagnostics, where genomics data is analyzed and viewed in a similar manner to plants.
In Brazil, the company announced in June a realignment plan consistent with its overall shift from bioenergy toward food and feed opportunities. Current cost reductions implemented under the plan are expected to deliver cash savings of up to approximately $4 to $5 million in fiscal year 2016, primarily through restructuring the company's Brazilian operations. Ceres expects to make additional cost reductions which are expected to save up to approximately $2 to $3 million in fiscal year 2016. The company is exploring discussions with additional local partners and collaborators to support the continued development and commercialization of its technology in Brazil. The company also plans to expand its sugarcane trait development activities for the Brazilian sugarcane market. Separately, the company reported that for the recently completed 2014-2015 sorghum growing season in Brazil, it had achieved continued progress from its product development pipeline, including the highest ethanol yields achieved to date at industrial scale by one of its sweet sorghum products. A number of its pre-commercial high biomass sorghum and sweet sorghum hybrids also met or exceeded field performance targets in multiple regions. Based on anecdotal reports, the company's commercial high-biomass sorghum plantings widely outyielded competing products this season at locations where side-by-side comparisons were available, however, yields were below company targets due, in part, to delays during planting and less than optimal harvest practices.
Third Quarter Financial Results
Total revenues increased by $0.3 million to $1.1 million for the quarter ended May 31, 2015 compared to the same period last year. Revenue from collaborative research and government grants increased by $0.3 million primarily due to the recognition of revenue following the completion of work under the company's various collaboration agreements. Product sales were relatively unchanged.
Total cost and operating expenses decreased by $1.5 million to $7.0 million for the quarter ended May 31, 2015 compared to the same period last year.
Cost of product sales increased by $0.3 million to $0.9 million for the quarter ended May 31, 2015 compared to the same period last year. Cost of product sales in Brazil increased by $0.2 million primarily due to increased expenses related to biomass produced under the company's sales incentive and promotional programs for the 2014-2015 growing season. In the U.S., expenses increased by $0.1 million primarily due to increased seed production costs for Ceres' U.S. sorghum business.
Research and development expenses decreased by $1.1 million to $2.5 million for the quarter ended May 31, 2015 compared to the same period last year primarily due to reduced personnel and related expenses in the U.S.
Selling, general and administrative expenses decreased by $0.2 million to $3.6 million for the quarter ended May 31, 2015 compared to the same period last year primarily due to reduced personnel and related expenses in the U.S. and Brazil.
For the quarter ended May 31, 2015, Ceres reported a net loss of $5.9 million, or $0.98 per share, compared to a net loss of $7.7 million, or $1.35 per share, for the quarter ended May 31, 2014.
At May 31, 2015, cash and cash equivalents and marketable securities totaled $9.1 million.